• The FDA has approved Attruby (acoramidis) for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), addressing both wild-type and variant forms of the disease.
• Attruby, an oral TTR stabilizer, demonstrated a significant reduction in cardiovascular death and cardiovascular-related hospitalizations in the Phase 3 ATTRibute-CM trial.
• The approval marks Attruby as the first and only therapy with a label specifying near-complete stabilization of transthyretin (TTR), targeting the underlying cause of ATTR-CM.
• Clinical data showed Attruby improved quality of life and reduced all-cause mortality and cardiovascular hospitalization as early as three months after treatment initiation.